2A). for NET formation and associated DNA release in neutrophils. Serum levels of anti-PAD4 antibodies (Ab) were elevated in CF (p=0.0147) compared to HC and showed an inverse correlation with a measure of lung function, FEV1% predicted (r = ?0.5020, p=0.015), as did MPO levels (r = ?0.4801, p=0.0026). Anti-PAD4 Ab levels in CF sera associated with lung infection by =37232021Gender?%female42.1%30.4%60.0%95.2%?%male57.9%69.6%40.0%4.8%Age (yrs, mean+/?S.D.)30.4+/?9.429.2+/?11.632.5+/?4.845.1+/12.6 Open in a separate window CF patients CF subjects were patients followed at the Adult CF Clinic at Emory University who had signed informed consent to provide blood samples and clinical data for the CF Biospecimen Repository in accordance with the Emory University IRB (Emory #00042577). All patients had the diagnosis of CF confirmed by pilocarpine iontophoresis sweat testing and/or CFTR gene mutation analysis showing the presence of two disease causing mutations. Blood was drawn when the subject had been clinically stable for a minimum of three weeks and no new medications had been started during the prior three weeks. Four milliliters of blood were drawn into a silicone coated tube and allowed to clot at room temperature for 30 minutes. The tube was centrifuged, serum aliquotted, and stored at ?80C until shipped to UGA on dry ice for analysis. Sputum cultures in those patients who could expectorate sputum and throat cultures were taken on the day of the blood draw and the presence or absence of or as identified by the clinical microbiology laboratory was noted. Baseline lung function was defined as is done for Slc7a7 the CF Foundation Patient Registry which is the average of the best percent predicted forced expired volume in one second (FEV1) for each quarter of the calendar year. Blood and clinical data were collected during the period of 2010 to 2016. SLE patients Systemic Bendazac L-lysine lupus erythematosus (SLE) patients meeting four or more American College of Rheumatology lupus criteria (22) were recruited at the University of Michigan lupus clinic under IRB-Med 00066116. All patients underwent written, informed consent and were treated according to the declaration of Helsinki. Five mL of blood was collected from SLE patients in a serum separator tube, aliquoted and frozen at ?80C. They were sent on dry-ice to UGA for analysis. Patients with Rheumatoid Arthritis Serum from rheumatoid arthritis (RA) patients attending rheumatology clinics were obtained from the University of Alabama at Birmingham (UAB) Rheumatology Arthritis Database and Repository (RADAR). All patients met the 1987 ARA (now ACR) or 2010 ACR/EULAR classification criteria. All data and samples were obtained in accordance with the Bendazac L-lysine UAB IRB. Standard techniques for venipuncture and isolation of serum were used. Serum was processed from SST tubes almost exclusively on the same day as venipuncture. Serum samples were aliquoted, frozen at ?80C and shipped on dry ice to UGA to minimize freeze/thaw cycles. Myeloperoxidase and neutrophil elastase ELISA Commercial ELISA kits were used to determine serum levels of MPO (R&D Systems, DuoSet, Minneapolis, MN, USA) and complexes of NE and alpha-proteinase inhibitor (PI) (Abcam, Cambridge, MA) according to the manufacturers instructions. Results are expressed as ng/ml in undiluted human serum. The experimental limits of detection were: 125.0 pg/ml (MPO ELISA) and 78.1 pg/ml (NE/alpha1-PI Bendazac L-lysine ELISA). DNA quantification The concentration of cell-free double stranded DNA in human serum samples was quantitated with the Quant-iT? PicoGreen? dsDNA Assay Kit (ThermoFisher Scientific, Grand Island, NY, USA). Serum samples were diluted 10 to 100Cfold in sterile PBS and Bendazac L-lysine PicoGreen reagent was added according to manufacturers instructions. DNA doses were quantitated using a known DNA standard and are expressed as ng/ml in undiluted human serum. Quantification of NETs.